Clearmind Medicine, Inc. (CMND)
1.68
0.00 (0.00%)
USD |
NASDAQ |
Aug 25, 11:40
Clearmind Medicine Enterprise Value : -11.80M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -11.80M |
| August 21, 2026 | -11.73M |
| August 20, 2026 | -11.74M |
| August 19, 2026 | -11.56M |
| August 18, 2026 | -11.51M |
| August 17, 2026 | -11.58M |
| August 14, 2026 | -11.61M |
| August 13, 2026 | -11.62M |
| August 12, 2026 | -11.83M |
| August 11, 2026 | -11.87M |
| August 10, 2026 | -11.88M |
| August 07, 2026 | -11.85M |
| August 06, 2026 | -11.72M |
| August 05, 2026 | -11.71M |
| August 04, 2026 | -11.76M |
| August 03, 2026 | -11.85M |
| July 31, 2026 | -11.79M |
| July 30, 2026 | -11.86M |
| July 29, 2026 | -12.02M |
| July 28, 2026 | -12.02M |
| July 27, 2026 | -11.86M |
| July 24, 2026 | -11.87M |
| July 23, 2026 | -11.82M |
| July 22, 2026 | -11.81M |
| July 21, 2026 | -11.84M |
| Date | Value |
|---|---|
| July 20, 2026 | -11.60M |
| July 17, 2026 | -11.53M |
| July 16, 2026 | -11.48M |
| July 15, 2026 | -11.65M |
| July 14, 2026 | -11.54M |
| July 13, 2026 | -11.48M |
| July 10, 2026 | -11.44M |
| July 09, 2026 | -11.40M |
| July 08, 2026 | -11.37M |
| July 07, 2026 | -11.35M |
| July 06, 2026 | -11.12M |
| July 02, 2026 | -11.10M |
| July 01, 2026 | -11.16M |
| June 30, 2026 | -11.27M |
| June 29, 2026 | -11.16M |
| June 26, 2026 | -11.08M |
| June 25, 2026 | -10.97M |
| June 24, 2026 | -10.78M |
| June 23, 2026 | -10.48M |
| June 22, 2026 | -10.47M |
| June 18, 2026 | -10.38M |
| June 17, 2026 | -10.31M |
| June 16, 2026 | -10.31M |
| June 15, 2026 | -10.07M |
| June 12, 2026 | -10.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | -0.0413M |
| NervGen Pharma Corp. | 151.65M |
| Milestone Pharmaceuticals, Inc. | 100.70M |
| Lexaria Bioscience Corp. | 13.49M |
| Target Group, Inc. (Canada) | 11.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.048M |
| Total Expenses (Quarterly) | 2.048M |
| EPS Diluted (Quarterly) | -6.781 |
| Earnings Yield | -11.07K% |
| Normalized Earnings Yield | -13266.71 |